Population nutrikinetics of green tea extract

Catharina Scholl, Anna Lepper, Thorsten Lehr, Nina Hanke, Katharina Luise Schneider, Jürgen Brockmöller, Thomas Seufferlein, Julia Carolin Stingl, Catharina Scholl, Anna Lepper, Thorsten Lehr, Nina Hanke, Katharina Luise Schneider, Jürgen Brockmöller, Thomas Seufferlein, Julia Carolin Stingl

Abstract

Green tea polyphenols may contribute to the prevention of cancer and other diseases. To learn more about the pharmacokinetics and interindividual variation of green tea polyphenols after oral intake in humans we performed a population nutrikinetic study of standardized green tea extract. 84 healthy participants took green tea extract capsules standardized to 150 mg epigallocatechin-gallate (EGCG) twice a day for 5 days. On day 5 catechin plasma concentrations were analyzed using non-compartmental and population pharmacokinetic methods. A strong between-subject variability in catechin pharmacokinetics was found with maximum plasma concentrations varying more than 6-fold. The AUCs of EGCG, EGC and ECG were 877.9 (360.8-1576.5), 35.1 (8.0-87.4), and 183.6 (55.5-364.6) h*μg/L respectively, and the elimination half lives were 2.6 (1.8-3.8), 3.9 (0.9-10.7) and 1.8 (0.8-2.9) h, respectively. Genetic polymorphisms in genes of the drug transporters MRP2 and OATP1B1 could at least partly explain the high variability in pharmacokinetic parameters. The observed variability in catechin plasma levels might contribute to interindividual variation in benefical and adverse effects of green tea polyphenols. Our data could help to gain a better understanding of the causes of variability of green tea effects and to improve the design of studies on the effects of green tea polyphenols in different health conditions.

Trial registration: ClinicalTrials.gov: NCT01360320.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Consort flowchart.
Fig 1. Consort flowchart.
Fig 2. Schematic representation of the study…
Fig 2. Schematic representation of the study design and blood sampling.
The experiment includes one pre-study day and 5 days treatment with standardized green tea extract (GTE). Blood sampling for nutrikinetics takes place on day 5. Dosing of GTE: day 1–4: twice a day (≙ 2 x 150 mg EGCG/day), day 5: after overnight fasting intake of one GTE capsule (150 mg EGCG).
Fig 3. Individual measured plasma concentration-time profiles…
Fig 3. Individual measured plasma concentration-time profiles of EGCG, EGC and ECG on the 5th day of oral administration.
Fig 4. Correlation between the AUCs of…
Fig 4. Correlation between the AUCs of the different green tea catechins.
Distribution histograms of the AUCs and scatter plots showing the correlation between the AUCs of the different green tea catechins. ρ: Pearson correlation coefficients: AUCEGCG−AUCEGC: 0.3058 (p = 0.0052); AUCEGCG−AUCECG: 0.9248 (p<0.0001), AUCEGC−AUCECG: 0.4537 (p<0.0001).
Fig 5. PopPK models.
Fig 5. PopPK models.
Structures of the three independently developed PopPK models employing two-compartment nested models with different descriptions of the absorption processes for the gallate (EGCG, ECG) and non-gallate (EGC) green tea catechins. The depot compartment (Depot) represents the gastrointestinal tract, from where the catechins are absorbed into the central volume of distribution (Vcentral), representing the blood and quickly equilibrating tissues such as liver and kidney. Vperiph.: peripheral volume of distribution, D1: dissolution duration, ka: absorption time constant, Q: intercompartmental clearance, CL: clearance from Vcentral.
Fig 6. Visual predictive checks of the…
Fig 6. Visual predictive checks of the simulation of 1000 individual plasma concentration-time profiles.
Visual predictive checks showing the medians (black lines) and corresponding 90% prediction intervals (shaded grey areas) of the simulation of 1000 individual plasma concentration-time profiles using the final PopPK model parameters of EGCG, EGC and ECG, overlaid with the respective observed data (circles). Linear (left panel) and logarithmic (right panel) presentation of plasma concentrations.
Fig 7. Goodness-of-fit plots of the final…
Fig 7. Goodness-of-fit plots of the final PopPK models of EGCG, EGC and ECG.
Observed (x-axis) vs. predicted (y-axis) plasma concentrations (black circles) scattered around the line of identity. Population predictions (left panel) and individual plasma concentration predictions (right panel) of all three catechins.
Fig 8. Simulation of single dose and…
Fig 8. Simulation of single dose and steady-state plasma concentrations using the final PopPK model parameters of EGCG, EGC and ECG.
Shown are the predicted medians (black lines) and corresponding 90% prediction intervals (shaded grey areas) of the simulation of 1000 individual plasma concentration-time profiles for each green tea catechin.

References

    1. Balentine DA, Wiseman SA, Bouwens LC (1997) The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37: 693–704. doi:
    1. Johnson R, Bryant S, Huntley AL (2012) Green tea and green tea catechin extracts: an overview of the clinical evidence. Maturitas 73: 280–287. doi:
    1. Kanwar J, Taskeen M, Mohammad I, Huo C, Chan TH, et al. (2012) Recent advances on tea polyphenols. Front Biosci (Elite Ed) 4: 111–131.
    1. Yuan JM (2013) Cancer prevention by green tea: evidence from epidemiologic studies. Am J Clin Nutr 98: 1676S–1681S. doi:
    1. Rahmani AH, Al Shabrmi FM, Allemailem KS, Aly SM, Khan MA (2015) Implications of Green Tea and Its Constituents in the Prevention of Cancer via the Modulation of Cell Signalling Pathway. Biomed Res Int 2015: 925640 doi:
    1. Chow HH, Hakim IA (2011) Pharmacokinetic and chemoprevention studies on tea in humans. Pharmacol Res 64: 105–112. doi:
    1. Stingl JC, Ettrich T, Muche R, Wiedom M, Brockmoller J, et al. (2011) Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. BMC Cancer 11: 360 doi:
    1. Ullmann U, Haller J, Decourt JD, Girault J, Spitzer V, et al. (2004) Plasma-kinetic characteristics of purified and isolated green tea catechin epigallocatechin gallate (EGCG) after 10 days repeated dosing in healthy volunteers. Int J Vitam Nutr Res 74: 269–278. doi:
    1. Ullmann U, Haller J, Decourt JP, Girault N, Girault J, et al. (2003) A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 31: 88–101. doi:
    1. Henning SM, Niu Y, Liu Y, Lee NH, Hara Y, et al. (2005) Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 16: 610–616. doi:
    1. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, et al. (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9: 3312–3319.
    1. Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, et al. (2002) Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11: 1025–1032.
    1. Fung ST, Ho CK, Choi SW, Chung WY, Benzie IF (2013) Comparison of catechin profiles in human plasma and urine after single dosing and regular intake of green tea (Camellia sinensis). Br J Nutr 109: 2199–2207. doi:
    1. Warden BA, Smith LS, Beecher GR, Balentine DA, Clevidence BA (2001) Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 131: 1731–1737.
    1. Renouf M, Guy P, Marmet C, Longet K, Fraering AL, et al. (2010) Plasma appearance and correlation between coffee and green tea metabolites in human subjects. Br J Nutr 104: 1635–1640. doi:
    1. Henning SM, Wang P, Abgaryan N, Vicinanza R, de Oliveira DM, et al. (2013) Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. Mol Nutr Food Res 57: 483–493. doi:
    1. Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, et al. (2005) Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11: 4627–4633. doi:
    1. Nakagawa K, Okuda S, Miyazawa T (1997) Dose-dependent incorporation of tea catechins, (-)-epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma. Biosci Biotechnol Biochem 61: 1981–1985.
    1. Hodgson AB, Randell RK, Mahabir-Jagessar TK, Lotito S, Mulder T, et al. (2014) Acute effects of green tea extract intake on exogenous and endogenous metabolites in human plasma. J Agric Food Chem 62: 1198–1208. doi:
    1. Chen L, Lee MJ, Li H, Yang CS (1997) Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 25: 1045–1050.
    1. Lambert JD, Lee MJ, Lu H, Meng X, Hong JJ, et al. (2003) Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 133: 4172–4177.
    1. Henning SM, Choo JJ, Heber D (2008) Nongallated compared with gallated flavan-3-ols in green and black tea are more bioavailable. J Nutr 138: 1529S–1534S.
    1. Sang S, Lambert JD, Ho CT, Yang CS (2011) The chemistry and biotransformation of tea constituents. Pharmacol Res 64: 87–99. doi:
    1. Lambert JD, Sang S, Yang CS (2007) Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol Pharm 4: 819–825. doi:
    1. van Duynhoven J, Vaughan EE, Jacobs DM, Kemperman RA, van Velzen EJ, et al. (2011) Metabolic fate of polyphenols in the human superorganism. Proc Natl Acad Sci U S A 108 Suppl 1: 4531–4538.
    1. Chen D, Wang CY, Lambert JD, Ai N, Welsh WJ, et al. (2005) Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol 69: 1523–1531. doi:
    1. Lu H, Meng X, Yang CS (2003) Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos 31: 572–579.
    1. Nagai M, Conney AH, Zhu BT (2004) Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase. Drug Metab Dispos 32: 497–504. doi:
    1. Lorenz M, Paul F, Moobed M, Baumann G, Zimmermann BF, et al. (2014) The activity of catechol-O-methyltransferase (COMT) is not impaired by high doses of epigallocatechin-3-gallate (EGCG) in vivo. Eur J Pharmacol 740: 645–651. doi:
    1. Lee MJ, Wang ZY, Li H, Chen L, Sun Y, et al. (1995) Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev 4: 393–399.
    1. Vaidyanathan JB, Walle T (2002) Glucuronidation and sulfation of the tea flavonoid (-)-epicatechin by the human and rat enzymes. Drug Metab Dispos 30: 897–903.
    1. Wang T, Cook I, Leyh TS (2016) Isozyme Specific Allosteric Regulation of Human Sulfotransferase 1A1. Biochemistry 55: 4036–4046. doi:
    1. Coughtrie MW, Johnston LE (2001) Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance. Drug Metab Dispos 29: 522–528.
    1. Lu H, Meng X, Li C, Sang S, Patten C, et al. (2003) Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab Dispos 31: 452–461.
    1. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS (2003) Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun 310: 222–227.
    1. Vaidyanathan JB, Walle T (2003) Cellular uptake and efflux of the tea flavonoid (-)epicatechin-3-gallate in the human intestinal cell line Caco-2. J Pharmacol Exp Ther 307: 745–752. doi:
    1. Knop J, Misaka S, Singer K, Hoier E, Muller F, et al. (2015) Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One 10: e0139370 doi:
    1. Albassam AA, Markowitz JS (2017) An Appraisal of Drug-Drug Interactions with Green Tea (Camellia sinensis). Planta Med 83: 496–508. doi:
    1. Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, et al. (2011) Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. Ther Drug Monit 33: 632–643. doi:
    1. Sheiner LB (1984) Analysis of pharmacokinetic data using parametric models—1: Regression models. J Pharmacokinet Biopharm 12: 93–117.
    1. van Velzen EJ, Westerhuis JA, van Duynhoven JP, van Dorsten FA, Grun CH, et al. (2009) Phenotyping tea consumers by nutrikinetic analysis of polyphenolic end-metabolites. J Proteome Res 8: 3317–3330. doi:
    1. van Velzen EJJ, Westerhuis JA, Grün CH, Jacobs DM, Eilers PHC, et al. (2014) Population-based nutrikinetic modeling of polyphenol exposure. Metabolomics 10: 1059–1073.
    1. Tagashira T, Choshi T, Hibino S, Kamishikiryou J, Sugihara N (2012) Influence of gallate and pyrogallol moieties on the intestinal absorption of (-)-epicatechin and (-)-epicatechin gallate. J Food Sci 77: H208–215. doi:
    1. Kadowaki M, Sugihara N, Tagashira T, Terao K, Furuno K (2008) Presence or absence of a gallate moiety on catechins affects their cellular transport. J Pharm Pharmacol 60: 1189–1195. doi:
    1. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, et al. (2001) Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10: 53–58.
    1. Isomura T, Suzuki S, Origasa H, Hosono A, Suzuki M, et al. (2016) Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized controlled trials. Eur J Clin Nutr.
    1. Mazzanti G, Di Sotto A, Vitalone A (2015) Hepatotoxicity of green tea: an update. Arch Toxicol 89: 1175–1191. doi:
    1. Bruhn O, Cascorbi I (2014) Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 10: 1337–1354. doi:
    1. Konig J, Cui Y, Nies AT, Keppler D (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278: G156–164. doi:
    1. Lee HH, Ho RH Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol 83: 1176–1184. doi:
    1. Gong IY, Kim RB Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 28: 4–18.
    1. Inoue-Choi M, Yuan JM, Yang CS, Van Den Berg DJ, Lee MJ, et al. (2010) Genetic Association Between the COMT Genotype and Urinary Levels of Tea Polyphenols and Their Metabolites among Daily Green Tea Drinkers. Int J Mol Epidemiol Genet 1: 114–123.
    1. Miller RJ, Jackson KG, Dadd T, Nicol B, Dick JL, et al. (2012) A preliminary investigation of the impact of catechol-O-methyltransferase genotype on the absorption and metabolism of green tea catechins. Eur J Nutr 51: 47–55. doi:

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner